Signaling by growth/differentiation factor 5 through the bone morphogenetic protein receptor type IB protects neurons against kainic acid-induced neurodegeneration

Neurosci Lett. 2017 Jun 9:651:36-42. doi: 10.1016/j.neulet.2017.04.055. Epub 2017 Apr 27.

Abstract

Growth/differentiation factor-5 (GDF-5), a member of the transforming growth factor-beta (TGF-β) superfamily, has been shown to protect rat dopaminergic neurons against insult both in embryonic neuronal culture and in Parkinson's disease models. However, whether GDF-5 exerts neuroprotective effects in hippocampal neurons is unclear. Here, we show that both mRNA levels and protein levels of GDF-5 are decreased in the mouse hippocampus upon kainic acid (KA) treatment. KA induced dramatic neuronal loss specifically in the cornu ammonis 1 (CA1) and CA3 areas of the mouse hippocampus, while intracerebral infusion of GDF-5 prevented this neuronal loss. The neuroprotective effects of GDF-5 were recapitulated by constitutively active bone morphogenetic protein type IB receptor (BMPRIB-CA) and could be blocked by BMPRI kinase inhibitor LDN-193189. Furthermore, the neuroprotective effects of GDF-5 were mediated through the prevention of apoptosis, which was indicated by terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) staining and reduced cleaved caspase 3 expression level. Thus, we conclude that GDF-5 protects hippocampal neurons against KA-induced neurodegeneration by signaling through BMPRIB, suggesting a therapeutic potential for GDF-5 in neurodegenerative diseases.

Keywords: Bone morphogenetic protein type IB receptor; Growth/differentiation factor-5; Hippocampal neuron; Kainic acid; Neurodegenerative disease.

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Bone Morphogenetic Protein Receptors, Type I / metabolism*
  • Growth Differentiation Factor 5 / administration & dosage*
  • Growth Differentiation Factor 5 / metabolism*
  • Hippocampus / drug effects*
  • Hippocampus / metabolism
  • Hippocampus / pathology
  • Kainic Acid / administration & dosage
  • Mice
  • Neurodegenerative Diseases / chemically induced
  • Neurodegenerative Diseases / drug therapy*
  • Neurodegenerative Diseases / metabolism
  • Neurons / drug effects*
  • Neurons / metabolism
  • Neurons / pathology
  • Neuroprotective Agents / administration & dosage*
  • RNA, Messenger / metabolism
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / metabolism
  • Signal Transduction / drug effects

Substances

  • Growth Differentiation Factor 5
  • Neuroprotective Agents
  • RNA, Messenger
  • Recombinant Proteins
  • Bmpr1b protein, mouse
  • Bone Morphogenetic Protein Receptors, Type I
  • Kainic Acid